Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feld

Showing results (311-320 of 451) with videos related to

Pageof 46
Sort By:
CMAJ Open|December 27, 2016
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive studyAlison D Marshall, Sahar Saeed, Lisa Barrett, et al.
Hepatology Communications|March 8, 2021
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS StudyBertus Eksteen, Christopher L Bowlus, Aldo J Montano-Loza, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
JCO Oncology Practice|June 14, 2022
Practical Implementation of Universal Hepatitis B Virus Screening for Patients With CancerJessica P Hwang, Andy S Artz, Parth Shah, et al.
The American Journal of Gastroenterology|February 2, 2023
Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment TrialJordan J Feld, Abdus S Wahed, Michael Fried, et al.
Hepatology (Baltimore, Md.)|April 17, 2024
Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN TrialsMuhammad Atif Zahoor, Joshua B Feld, Hsing-Hua Sylvia Lin, et al.
Gastroenterology|September 22, 2010
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersJordan J Feld, Apurva A Modi, Ramy El-Diwany, et al.
Gastroenterology|April 29, 2008
Hepatic involvement and portal hypertension predict mortality in chronic granulomatous diseaseJordan J Feld, Nadeem Hussain, Elizabeth C Wright, et al.
Pageof 46

Showing results (311-320 of 451) with videos related to

Sort By:
Pageof 46
CMAJ Open|December 27, 2016
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive studyAlison D Marshall, Sahar Saeed, Lisa Barrett, et al.
Hepatology Communications|March 8, 2021
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS StudyBertus Eksteen, Christopher L Bowlus, Aldo J Montano-Loza, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 31, 2017
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosisTarik Asselah, Stefan Bourgeois, Stephen Pianko, et al.
The New England Journal of Medicine|April 12, 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinJordan J Feld, Kris V Kowdley, Eoin Coakley, et al.
JCO Oncology Practice|June 14, 2022
Practical Implementation of Universal Hepatitis B Virus Screening for Patients With CancerJessica P Hwang, Andy S Artz, Parth Shah, et al.
The American Journal of Gastroenterology|February 2, 2023
Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment TrialJordan J Feld, Abdus S Wahed, Michael Fried, et al.
Hepatology (Baltimore, Md.)|April 17, 2024
Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN TrialsMuhammad Atif Zahoor, Joshua B Feld, Hsing-Hua Sylvia Lin, et al.
Gastroenterology|September 22, 2010
S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersJordan J Feld, Apurva A Modi, Ramy El-Diwany, et al.
Gastroenterology|April 29, 2008
Hepatic involvement and portal hypertension predict mortality in chronic granulomatous diseaseJordan J Feld, Nadeem Hussain, Elizabeth C Wright, et al.
Pageof 46